Psoriatic arthritis: What the dermatologist needs to know, part 2;Artritis psoriásica. Lo que el dermatólogo debe saber (Parte 2)

Actas Dermo-Sifiliograficas

Volumn 101, Issue 9, 2010, Pages 742-748

  Lopez Ferrer A ^a   Torrente Segarra, V ^a   Puig, L ^a  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

Author keywords

Evaluation methods; Psoriasis; Psoriatic arthritis; Treatment

Indexed keywords

DISEASE SEVERITY; HUMAN; PROGNOSIS; PSORIASIS; PSORIATIC ARTHRITIS; REVIEW; TREATMENT RESPONSE;

EID: 78049384506     PISSN: 00017310     EISSN: 15782190     Source Type: Journal    
DOI: 10.1016/S1578-2190(10)70712-5     Document Type: Review

References (14)

1. P.J. Mease, C.E. Antoni, G.G. Gladman, and W.J. Taylor Psoriatic arthritis assessment tools in clinical trials Ann Rheum Dis 64 2005 49 54
2. J.M. Berthelot, A. Blanchais, T. Marhadour, B. le Goff, Y. Maugars, and A. Saraux Fluctuations in disease activity scores for inflammatory joint disease in clinical practice: do we need a solution? Joint Bone Spine 76 2009 126 128
3. P.J. Healy, and P.S. Helliwell Measuring clinical enthesitis in psoriatic arthritis: assessment of existing measures and development of an instrument specific to psoriatic arthritis Arthritis Rheum 59 2008 686 691
4. C.T. Ritchlin, A. Kavanaugh, D. Gladman, P.J. Mease, P. Helliwell, W.H. Boehncke Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) Ann Rheum Dis 68 2009 1387 1394
5. P.J. Mease Psoriatic arthritis assessment and treatment update Curr Opin Rheumatol 21 2009 348 355
6. E. Collantes, J.L. Fernández Sueiro, R. García-Vicua, J. Gratacs, J. Mulero, and S. Muñoz Fernández Actualizacin del consenso de la Sociedad EspañOla de Reumatolga sobre el uso de antagonistas del TNF-α en las espondiloartritis, incluida la artritis psoriásica Reumatol Clin 3 Supl2 2007 S261 S271
7. L. Puig Infliximab: patients selection Actas Dermosifiliogr 99 Suppl 4 2008 23 29
8. A. Kavanaugh, I. McInnes, P. Mease, G.G. Krueger, D. Gladman, and J. Gómez-Reino Golimumab, a new human tumor necrosis factor α antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis Arthr Rheum 60 2009 976 986
9. J.M. Jackson TNF-α inhibitors Dermatol Ther 20 2007 251 264
10. A.A. Saad, D.P.M. Symons, P.R. Noyce, and D.M. Ashcroft Risks and benefits of tumor necrosis factor-α inhibitors in the management of psoriatic arthritis: systematic review and metaanalysis of randomized controlled trial J Rheumatol 35 2008 883 890
11. P.J. Mease Spondyloarthritis update Bull NYU Hosp J Dis 66 2008 203 209
12. L.C. Coates, J. Fransen, and P.S. Helliwell Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment Ann Rheum Dis 69 2010 48 53
13. A. Kavanaugh, and J. Fransen Defining remission in psoriatic arthritis Clin Exp Rheumatol 24 Suppl. 43 2006 S83 S87
14. D.D. Gladman Psoriatic arthritis Dermatol Ther 22 2009 40 55